ライフサイエンスコーパス: valproic acid

1 nacetin, metribuzin, phenytoin, thiacloprid, valproic acid).

2 liperidone is similar to that of lithium and valproic acid.

3 when given patients with acute ingestions of valproic acid.

4 he so-called "mood stabilizers," lithium and valproic acid.

5 s of lamotrigine and phenobarbital caused by valproic acid.

6 , suppressed the transcriptional response to valproic acid.

7 well as Sp-mediated transcription induced by valproic acid.

8 monitored in all hepatitis C patients taking valproic acid.

9 me, accompanied by an increase in the use of valproic acid.

10 ion options for carbamazepine, diazepam, and valproic acid.

11 y relevant AEDs ethosuximide, lacosamide, or valproic acid.

12 treatment while enhanced in the presence of valproic acid.

13 bined with the histone-deacetylase inhibitor valproic acid.

14 gent, 5-azacytidine, and the HDAC inhibitor, valproic acid.

15 th ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their d

16 Valproic acid (2 mmolkg for 15 days, twice a day) revert

17 repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and al

18 bumin in the absence or presence of vehicle, valproic acid (300 mug/g body weight) or BAY11-7082 (400

19 to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment

20 ffects of polymyxin-B (a cytolytic peptide), valproic acid (a lipophilic drug), and amyloid-beta (a p

21 nd lenalidomide had synergistic effects with valproic acid [a histone deacetylase (HDAC) inhibitor] b

22 Both valproic acid, a class I HDAC inhibitor, and suberoylani

23 roduce infectious viruses in the presence of valproic acid, a histone deacetylase inhibitor and a nov

24 Moreover, valproic acid, a histone deacetylase inhibitor that we p

25 Finally, embryos treated with valproic acid, a known teratogen which affects somite se

26 ns experimentally, we exposed rat embryos to valproic acid, a second teratogen newly linked to autism

27 , including the selective class I antagonist valproic acid, activate the same genes prematurely and a

28 We report that valproic acid activates Wntdependent gene expression, si

29 Here, we show that valproic acid addition to liquid cultures of human CD34+

30 r in rat brain also was reduced by long-term valproic acid administration.

31 DACi (apicidin, MS-275, sodium butyrate, and valproic acid) all inhibit by approximately 90% TF activ

32 The local diffusion constants for valproate/valproic acid along the bilayer normal are found to be a

33 Finally, valproic acid also attenuated METH-induced decrease H4K1

34 cetylase inhibitors trichostatin A (TSA) and valproic acid also induced expression of the endogenous

35 Valproic acid and BAY11-7082 selectively diminished tumo

36 Both valproic acid and BAY11-7082 significantly attenuated th

37 We show that histone deacetylase inhibitors valproic acid and butyrate dampened AICDA/Aicda (AID) an

38 Anticonvulsant mood stabilizers, e.g., valproic acid and carbamazepine, and atypical antipsycho

39 As with valproic acid and carbamazepine, zonisamide (12.5 and 25

40 review the pathophysiology and toxicology of valproic acid and determine whether the literature suppo

41 , olanzapine, quetiapine, or haloperidol) or valproic acid and its derivatives (as a nonantipsychotic

42 pine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 9

43 The use of valproic acid and its derivatives as alternative agents

44 l, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an antidepressant

45 Valproic acid and lithium are effective antibipolar drug

46 creases did not differ significantly between valproic acid and other medications.

47 For benzocaine, valproic acid and phenacetin several transformation prod

48 Valproic acid and related compounds warrant further inve

49 Both valproic acid and suberoylanilide hydroxamic acid inhibi

50 and S100A4 in R-cells were downregulated by valproic acid and suberoylanilide hydroxamic acid treatm

51 Exposure to valproic acid and suberoylanilide hydroxamic acid was as

52 r cells with histone deacetylase inhibitors, valproic acid and suberoylanilide hydroxamic acid, resto

53 The CEDIA kit for valproic acid and three substrates, a colorimetric (chlo

54 Furthermore, valproic acid and trichostatin A have remarkably similar

55 n with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat.

56 Mood stabilizers (e.g., valproic acid) and antipsychotic drugs (APDs) are common

57 rases (5-Azacytidine), histone deacetylases (valproic acid), and G9a histone dimethyltransferase.

58 neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children with newly di

59 TSA, valproic acid, and MS-275 repressed cytokine-induced MMP

60 lls cultured in the absence of CHIR99021 and valproic acid, and multilineage differentiation ability

61 The effectiveness of HDAC inhibitors, valproic acid, and suberoylanilide hydroxamic acid, in m

62 c (PK) monitoring of ketamine, propofol, and valproic acid, and their metabolites was achieved in mic

63 Valproic acid, another mood stabilizer, also increased t

64 orresponding PI values for phenobarbital and valproic acid are 1.37 and 5.18, respectively.

65 Lithium, carbamazepine and valproic acid are effective mood-stabilizing treatments

66 Disulfiram and valproic acid are known to inhibit ALDH5A1 and are safe

67 Lithium and valproic acid are mood-stabilizing agents that are often

68 Ethosuximide and valproic acid are more effective than lamotrigine in the

69 anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treatin

70 dence, we calculate profiles for the neutral valproic acid as well as its water-soluble anionic conju

71 ortantly, the histone deacetylase inhibitor, valproic acid, blocked METH-induced decreased expression

72 hese B cell-intrinsic epigenetic mechanisms, valproic acid blunted class-switched and hypermutated T-

73 d and the commonly prescribed anticonvulsant valproic acid, both short-chain fatty acids (SCFAs), dra

74 as stable before addition of enfuvirtide and valproic acid, but declined thereafter.

75 Dictyostelium is sensitive to lithium and to valproic acid, but resistance to both is conferred by de

76 ropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopram were associ

77 t the anticonvulsant mood stabilizers (AMS), valproic acid, carbamazepine, and zonisamide, but not li

78 Valproic acid, chloral hydrate and newer-generation anti

79 e daily dose needed to maintain stable serum valproic acid concentration was 21% higher.

80 embryos, while non-teratogenic analogues of valproic acid do not inhibit histone deacetylase and do

81 mg/kg), phenobarbital (ED50 = 22 mg/kg), and valproic acid (ED50 = 133 mg/kg), which have PI values o

82 This effect was disrupted in both valproic acid-exposed and Fmr1 knockout mice but intact

83 Despite its effects on the motor nuclei, valproic acid exposure did not alter the further develop

84 going 12 weeks of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam).

85 a subset of patients from the Trial of Oral Valproic Acid for Retinitis Pigmentosa.

86 , combining three specific compounds, namely valproic acid, guanabenz, and a specific Caspase12 inhib

87 The action of valproic acid has been linked to both inositol depletion

88 Notably, valproic acid highly preserves the CD34 positivity after

89 r agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an est

90 Valproic acid, however, acts through a distinct pathway

91 short-chain fatty acids (sodium butyrate and valproic acid); hydroxamic acids (oxamflatin, Scriptaid,

92 re GR transcriptome and found that the KDACi valproic acid impairs the ability of agonist-bound GR to

93 reatment with paliperidone, lithium salt, or valproic acid in order to find similarities or differenc

94 fects and could also explain the efficacy of valproic acid in the treatment of bipolar disorder.

95 y distinct models of autism: mice exposed to valproic acid in utero and Fmr1 knockout mice.

96 or three AEDs (carbamazepine, phenytoin, and valproic acid), in the presence of serum, correlate well

97 Here, we show that valproic acid increases levels of exon 7-containing SMN

98 As the use of valproic acid increases, the number of both accidental a

99 histone deacetylase provides a mechanism for valproic acid-induced birth defects and could also expla

100 We find that valproic acid-induced expression of Galpha(i2) is inhibi

101 Valproic acid-induced gene expression has been attribute

102 Using K562 cells, we have studied valproic acid-induced transcription from the human Galph

103 es the survival rate of patients who develop valproic-acid-induced hepatotoxicity.

104 This is paralleled by more reports of valproic-acid-induced toxicity.

105 he use of carnitine as a treatment for acute valproic-acid-induced toxicity.

106 C) inhibitors, including sodium butyrate and valproic acid, induces 15-PGDH expression.

107 Static and kinetic properties of valproic acid interacting with fully hydrated dipalmitoy

108 ation of the class I-specific HDAC inhibitor valproic acid into bromodeoxyuridine (BrdU)-infused rats

109 Valproic acid is a safe and widely used neurologic agent

110 Valproic acid is a short branched fatty acid used as an

111 Interestingly, we show that valproic acid is a weak inhibitor of HDAC3 (IC(50) = 5.5

112 Valproic acid is a widely used anticonvulsant that has r

113 Valproic acid is frequently not recommended for patients

114 Valproic acid is widely used to treat epilepsy and bipol

115 bstrates of the same enzymes (eg, tiagabine, valproic acid, lamotrigine, and topiramate).

116 present with coma, rising ammonia level, or valproic acid levels greater than 450 mg/l.

117 Valproic acid, like trichostatin A, also activates trans

118 ly pregnancy - thalidomide, misoprostol, and valproic acid; maternal rubella infection; and the organ

119 Use of valproic acid may be possible for some patients with hep

120 Valproic acid may increase SMN levels both by activating

121 At therapeutic levels, valproic acid mimics the histone deacetylase inhibitor t

122 a cells were treated with cytokines and TSA, valproic acid, MS-275, or siRNA, and quantitative revers

123 that the gene expression-inducing effect of valproic acid occurs, in part, through the Sp family of

124 l, our results relate the changes induced by valproic acid on chromatin accessibility with the enhanc

125 s factor-alpha in the absence or presence of valproic acid or BAY11-7082 in vitro.

126 ad, exposing adult mice treated acutely with valproic acid or carrying a targeted deletion of the Nog

127 proach where class I HDAC inhibitors such as valproic acid or MS-275 (entinostat) appear to counterac

128 drome, is usually treated with ethosuximide, valproic acid, or lamotrigine.

129 ddition of the histone deacetylase inhibitor valproic acid partially reverses the reduced globin gene

130 cause the total therapeutic concentration of valproic acid ranges from 275 to 700 mum in adults, thes

131 s using the distance between the bilayer and valproic acid respective centers-of-mass along the bilay

132 show that two small molecules, CHIR99021 and valproic acid, synergistically maintain self-renewal of

133 in nuclear extracts from cells treated with valproic acid than in control cells.

134 Attentional dysfunction was more common with valproic acid than with ethosuximide (in 49% of the chil

135 euroactive carriers, namely, nicotinic acid, valproic acid, theophylline-7-acetic acid, and choline,

136 we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in

137 When cells were treated with valproic acid to induce neuronal differentiation, each o

138 lproex (DVX), which is chemically related to valproic acid, to enhance DA and ACh efflux in the HIP a

139 nable to use carnitine for documented severe valproic acid toxicity, particularly in cases where pati

140 Moreover, valproic acid treatment increases histone H4 acetylation

141 Resveratrol and valproic acid treatment of one of the CSC lines resulted

142 ALT changes in 564 individuals beginning valproic acid treatment were examined.

143 alanine aminotransferase (ALT) values during valproic acid treatment.

144 orrhagic shock/resuscitation was restored by valproic acid treatment.

145 entiate along the megakaryocyte lineage upon valproic acid treatment.

146 Assuming protonation of valproic acid upon association with--or insertion into--

147 and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute mye

148 recent report that short-term treatment with valproic acid (VA) might accelerate the decay of the lat

149 the basis of in vitro synergistic effects of valproic acid (VPA) and all-trans retinoic acid with che

150 ound that both histone deacetylase inhibitor valproic acid (VPA) and DNA methylation inhibitor 5-azac

151 by the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and enhanced by the narrow-spectrum

152 Here, we tested 2 small molecules, valproic acid (VPA) and lithium (Li), to inhibit differe

153 induced by viral infection, is inhibited by valproic acid (VPA) and other histone deacetylase inhibi

154 tive to apoptosis induced by HDAC inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid

155 sensitive to histone deacetylase inhibitors valproic acid (VPA) and trichostatin A (TSA), recapitula

156 the histone deacetylase inhibitors (HDACis) valproic acid (VPA) and vorinostat.

157 stabilising drugs such as lithium (LiCl) and valproic acid (VPA) are the first line agents for treati

158 Lithium and valproic acid (VPA) are two primary drugs used to treat

159 (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect

160 n which we expose Xenopus laevis tadpoles to valproic acid (VPA) during a critical time point in brai

161 three etiologically distinct models-in utero valproic acid (VPA) exposure, CNTNAP2 knockout and FMR1

162 Valproic acid (VPA) has been widely used for decades to

163 Valproic acid (VPA) has been widely used in clinics for

164 Prenatal exposure to valproic acid (VPA) in humans has been associated with a

165 abine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia,

166 dministration of lithium chloride (LiCl) and valproic acid (VPA) in rats.

167 suggested that the nonlinear disposition of valproic acid (VPA) in the rat may be due to nonlinear d

168 nous rat model of ASD induced by exposure to valproic acid (VPA) in utero.

169 The mood-stabilizing agents lithium and valproic acid (VPA) increase DNA binding activity and tr

170 istone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of quiescent p

171 ly, combining NPI-0052 with either MS-275 or valproic acid (VPA) induced greater levels of cell death

172 atment with the mood stabilizers lithium and valproic acid (VPA) induces synergistic neuroprotective

173 Here, we report that both lithium as well as valproic acid (VPA) inhibit beta-amyloid peptide (Abeta)

174 Valproic acid (VPA) is a proposed treatment for RP and o

175 Valproic acid (VPA) is a widely prescribed anticonvulsan

176 Valproic acid (VPA) is a widely used anticonvulsive agen

177 Valproic acid (VPA) is among the most teratogenic of com

178 Dams received 350 mg/kg of valproic acid (VPA) on day 11.5 (the day of neural tube

179 s study, the effects of the antiseizure drug valproic acid (VPA) on the expression of genes that regu

180 We show here that the antiepileptic drug valproic acid (VPA) potently blocked seizure-induced neu

181 itions and psychiatric disorders affected by valproic acid (VPA) ranges from control of seizure and m

182 e demonstrate that the mood-stabilizing drug valproic acid (VPA) reduces sCD40L levels in plasma samp

183 Delivery of valproic acid (VPA) to the human brain is relatively ine

184 emozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes i

185 Valproic acid (VPA) was found to enhance alpha7 integrin

186 Valproic acid (VPA) was the most effective HDACi, induci

187 ted that inhibiting class I HDACs, either by valproic acid (VPA), a class I specific HDAC inhibitor s

188 Here we report that valproic acid (VPA), a histone deacetylase inhibitor, en

189 associated with epigenetic changes and that valproic acid (VPA), a histone deacetylase inhibitor, ma

190 enous alpha-syn in neurons can be induced by valproic acid (VPA), a mood-stabilizer, anticonvulsant a

191 Valproic acid (VPA), a well-established therapy for seiz

192 Our laboratory has reported that valproic acid (VPA), an antiepileptic medication that ha

193 In particular, valproic acid (VPA), an HDAC inhibitor, improves reprogr

194 Valproic acid (VPA), an histone deacetylase inhibitor, i

195 of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute mye

196 f the histone deacetylase inhibitor (HDACi), valproic acid (VPA), and epirubicin in solid tumor malig

197 lase (HDAC) inhibitors trichostatin A (TSA), valproic acid (VPA), and FK228 potentiated ATRA inductio

198 inhibitor of glucose uptake and glycolysis), valproic acid (VPA), and the ketogenic diet.

199 Valproic acid (VPA), another SCFA and an HDAC inhibitor,

200 We determined that valproic acid (VPA), currently undergoing a phase II tri

201 f CB CD34+ cells with the most active HDACI, valproic acid (VPA), following an initial 16-hour cytoki

202 Histone deacetylase inhibitors, such as valproic acid (VPA), have also been shown to have antian

203 ow that an inhibitor of histone deacetylase, valproic acid (VPA), induced neuronal differentiation of

204 e first 10 postnatal days, administration of valproic acid (VPA), the specific inhibitor for histone

205 Valproic acid (VPA), which, like NaB, belongs to the sho

206 well as the anticonvulsant mood-stabilizers, valproic acid (VPA), zonisamide, and carbamazepine, but

207 um butyrate (NaB), trichostatin A (TSA), and valproic acid (VPA).

208 nostat (suberoylanilide hydroxamic acid) and valproic acid (VPA).

209 chanism of action of a well-known teratogen, valproic acid (VPA).

210 ancreatitis is due to the antiepileptic drug valproic acid (VPA).

211 atment with a histone deacetylase inhibitor, valproic acid (VPA).

212 ) is a chiral CNS-active amide derivative of valproic acid (VPA).

213 morphology in animals prenatally exposed to valproic acid (VPA).

214 A combination of cytokines and valproic acid (VPA): (1) promoted the greatest degree of

215 Therapeutic concentrations of valproic acid (VPA, 10-100 microM) inhibited both evoked

216 brain capillaries to the antiepileptic drug, valproic acid (VPA; 5 muM), significantly increased P-gl

217 (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence int

218 2.66; 95% CI, 1.65 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.4

219 ALT elevations with valproic acid were significantly greater among patients

220 edom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; o

221 gs, mood stabilizers such as lithium ion and valproic acid, which are used to treat bipolar disorder,

222 partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression

223 M30 in epilepsy toward health, most notably valproic acid, whose effect on M30 expression was replic